Peptides for Dry Eye Syndrome: Ocular Surface Repair, Tear Film Restoration, and Anti-Inflammatory Peptides

How peptide Targets Peptides for Dry Eye Syndrome

Dry eye disease (DED) is a multifactorial condition involving tear film instability, hyperosmolarity, ocular surface inflammation, and neurosensory abnormalities. The two primary subtypes — aqueous-deficient (insufficient tear production) and evaporative (meibomian gland dysfunction causing lipid layer deficiency) — both result in a self-perpetuating cycle of inflammation, epithelial damage, and further tear film disruption. Conventional treatments (artificial tears, cyclosporine drops, lifitegrast) manage symptoms and inflammation but do not directly promote ocular surface tissue repair.

Thymosin beta-4 (TB4) is the peptide with the most direct clinical relevance to dry eye. TB4 is naturally present in human tears and plays a documented role in corneal wound healing. It promotes corneal epithelial cell migration, reduces inflammation through NF-kB pathway modulation, and inhibits apoptosis of epithelial cells. RegeneRx Biopharmaceuticals developed RGN-259, a topical ophthalmic formulation of thymosin beta-4, which progressed through Phase 2 clinical trials for dry eye disease. Trial results demonstrated statistically significant improvements in both signs (corneal fluorescein staining — a measure of epithelial damage) and symptoms (ocular discomfort scores) compared to placebo. This represents some of the strongest clinical evidence for any peptide in ophthalmology. TB4's mechanism directly addresses the tissue damage component of dry eye that conventional anti-inflammatory treatments do not — it actually repairs the corneal surface rather than just suppressing the inflammatory cascade.

Lacritin is an endogenous tear glycoprotein and prosecretory peptide that stimulates tear secretion from lacrimal glands. It is deficient in the tears of dry eye patients. Recombinant lacritin and lacritin-derived peptides have shown ability to restore basal tear secretion and promote corneal epithelial cell survival in preclinical models. Unlike secretagogues that force tear production, lacritin restores the physiological secretory mechanism — it works through syndecan-1 receptors on lacrimal gland acinar cells to stimulate constitutive tear production.

BPC-157 has broader mucosal healing properties that extend conceptually to the ocular surface. While direct ocular studies are limited, BPC-157's documented effects on epithelial repair, angiogenesis modulation, and anti-inflammatory signaling are mechanistically relevant to the chronic ocular surface damage in DED. Vasoactive intestinal peptide (VIP), present in corneal nerves and lacrimal glands, has immunomodulatory effects that may address the neurogenic inflammation component of dry eye, particularly in cases with corneal nerve dysfunction.